Eli Lilly and Company, Johnson & Johnson, and Novo Nordisk A/S are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, or sell prescription and over-the-counter medicines. For investors, their value can be influenced by factors such as clinical-trial results, regulatory approvals, patent expirations, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE:LLY traded up $8.27 during trading hours on Thursday, reaching $1,445.56. 1,125,071 shares of the company's stock were exchanged, compared to its average volume of 2,955,327. The firm has a market capitalization of $1.36 trillion, a price-to-earnings ratio of 46.92, a P/E/G ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,460.00. The company has a 50-day moving average of $1,231.13 and a 200 day moving average of $1,106.42. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
JNJ traded up $4.08 during trading on Thursday, hitting $284.49. The stock had a trading volume of 2,252,001 shares, compared to its average volume of 7,929,332. The firm has a market capitalization of $684.84 billion, a P/E ratio of 43.13, a PEG ratio of 2.78 and a beta of 0.22. The company's 50-day moving average price is $266.67 and its 200 day moving average price is $249.23. Johnson & Johnson has a twelve month low of $193.45 and a twelve month high of $286.08. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02.
Read Our Latest Research Report on JNJ
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NYSE NVO traded down $0.47 during trading on Thursday, hitting $40.62. 10,789,903 shares of the company were exchanged, compared to its average volume of 16,322,432. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.84 and a quick ratio of 0.64. The firm's fifty day moving average price is $40.32 and its 200 day moving average price is $43.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market cap of $181.39 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 1.40 and a beta of 0.70.
Read Our Latest Research Report on NVO
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
